Centers | ||
|
|
|
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Edinburgh Drug Discovery | Therapeutic Accelerator Program (TAP) |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Test |
Partnerships |
Events |
Jobs |
Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all UCB To Fund "Mining the Human Microbiome" Project at HarvardUCB as agreed to fund and support a third research project called "Mining the Human Microbiome" as part of the UCB-Harvard Research Alliance. UCB will be providing $4.5 million over a period of three years to immunologists at Harvard to study the... View all |
No EVENTS for listing |
No Job Posts |
